PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)

Proprotein convertase subtilisin/kexin type 9 (PCSK9), as a vital modulator of low-density lipoprotein cholesterol (LDL-C) , is raised in hepatocytes and released into plasma where it binds to LDL receptors (LDLR), leading to their cleavage. PCSK9 adheres to the epidermal growth factor-like repeat A...

Full description

Bibliographic Details
Main Authors: Saeideh Sobati, Amir Shakouri, Mahdi Edalati, Daryoush Mohammadnejad, Reza Parvan, Javad Masoumi, Jalal Abdolalizadeh
Format: Article
Language:English
Published: Tabriz University of Medical Sciences 2020-08-01
Series:Advanced Pharmaceutical Bulletin
Subjects:
atherosclerosis
cholesterol
coronary heart disease
ldl
monoclonal antibody
pcsk9
Online Access:https://apb.tbzmed.ac.ir/PDF/apb-10-502.pdf

Internet

https://apb.tbzmed.ac.ir/PDF/apb-10-502.pdf

Similar Items